Sagimet BiosciencesSTU:0O2 +1.66%10 PB Ratio is 2.26 as of Jun. 29, 2026, which is 138% above its 10-year median of 0.95. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Sagimet Biosciences ranks better than 58.69% on this metric.
Sagimet Biosciences Inc stock PB Ratio (=2.25) is close to 2-year high of 2.25.
The historical rank and industry rank for Sagimet Biosciences's PB Ratio or its related term are showing as below:
STU:0O2'
s PB Ratio Range Over the Past 10 Years
Min: 0.36 Med: 0.95 Max: 2.68
Current: 2.25
During the past 7 years, Sagimet Biosciences's highest PB Ratio was 2.68. The lowest was 0.36. And the median was 0.95.
STU:0O2's PB Ratio is ranked better than 58.69% of 1232
companies
in the Biotechnology industry
Industry Median: 2.815
vs STU:0O2: 2.25
During the past 12 months, Sagimet Biosciences's average Book Value Per Share Growth Rate was -27.20% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Sagimet Biosciences was -14.30% per year. The lowest was -14.30% per year. And the median was -14.30% per year.
Back to Basics: PB Ratio
Sagimet Biosciences (STU:0O2) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sagimet Biosciences PB Ratio Related Terms
Sagimet Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sagimet Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sagimet Biosciences (STU:0O2) has a PB Ratio of 2.26 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sagimet Biosciences and its competitors. This is 138% above median its historical median of 0.95. Over the past decade, Sagimet Biosciences' PB Ratio has ranged from 0.36 to 2.68. According to the industry distribution chart, Sagimet Biosciences ranks #509 out of 1232 companies in the Biotechnology industry, placing it in the top 41.3%.
Is Sagimet Biosciences' PB Ratio too high?
Sagimet Biosciences' current PB Ratio of 2.26 is 138% above median its 10-year median of 0.95. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 2.68. The Biotechnology industry median PB Ratio is 2.82. Sagimet Biosciences' value of 2.26 is 19.7% below this industry median. Based on the distribution chart, Sagimet Biosciences ranks #509 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' PB Ratio compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #509 out of 1232 companies for PB Ratio. This puts Sagimet Biosciences in the upper half of its industry. The industry median PB Ratio is 2.82. Sagimet Biosciences' value of 2.26 is 19.7% below this benchmark. Historically, Sagimet Biosciences' own PB Ratio has ranged from 0.36 to 2.68 over the past decade. While the company's 10-year median is 0.95 vs. the industry median of 2.82, Sagimet Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sagimet Biosciences's current PB Ratio of 2.26 is 19.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current PB Ratio is 2.26, which is 138% above median its own 10-year median of 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current PB Ratio of 2.26. The current PB Ratio is 2.26, which is 138% above median its 10-year median of 0.95 and 19.7% below the Biotechnology industry median of 2.82. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current PB Ratio is 2.26 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
